Alliances
The research will focus on accelerating the capacities of BLU-222, an investigational therapy that Blueprint designed to target cyclin-dependent kinase 2 (CDK2).
The extension will see a new investment of nearly $1 billion, which AbbVie and Calico will split down the middle.
Regeneron and AstraZeneca are looking to research, develop, and eventually commercialize a new drug that targets GPR75, the gene associated with obesity.
The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers.
The companies will co-finance a clinical study to test the combination of SHP2 inhibitor BBP-398 and OPDIVO in treating patients with advanced solid tumors KRAS mutations.
Kodiak Sciences, an ophthalmology-focused biotech company, based in Palo Alto, Calif., reportedly turned down $125 million from Baker Bros after hitting a clinical milestone. The company’s decision to decline this funding was due in part to its “strong balance sheet” and “clinical trial progress.”
Lantern will reacquire the Irofulven program and evaluate its potential for advanced development to treat bladder and prostate cancers.
This week the pharma giant announced a second collaboration agreement with Connecticut-based Arvinas to develop and commercialize its PROTAC estrogen receptor protein degrader.
Mirimus and Biogen, AavantiBio and Aldevron, Exscientia and GT Apeiron Therapeutics announced strategic partnerships this morning.
The drug is a nucleoside reverse transcriptase translocation inhibitor, with the results presented at the virtual 11th International AIDS Society Conference on HIV Science.
PRESS RELEASES